JP2022537562A5 - - Google Patents
Info
- Publication number
- JP2022537562A5 JP2022537562A5 JP2021575438A JP2021575438A JP2022537562A5 JP 2022537562 A5 JP2022537562 A5 JP 2022537562A5 JP 2021575438 A JP2021575438 A JP 2021575438A JP 2021575438 A JP2021575438 A JP 2021575438A JP 2022537562 A5 JP2022537562 A5 JP 2022537562A5
- Authority
- JP
- Japan
- Prior art keywords
- rna
- construct
- fragment
- variant
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025081437A JP2025118871A (ja) | 2019-06-18 | 2025-05-14 | Rna構築物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1908729.5 | 2019-06-18 | ||
| GBGB1908729.5A GB201908729D0 (en) | 2019-06-18 | 2019-06-18 | RNA construct |
| PCT/GB2020/051465 WO2020254804A1 (en) | 2019-06-18 | 2020-06-18 | Rna construct |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025081437A Division JP2025118871A (ja) | 2019-06-18 | 2025-05-14 | Rna構築物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022537562A JP2022537562A (ja) | 2022-08-26 |
| JP2022537562A5 true JP2022537562A5 (cg-RX-API-DMAC7.html) | 2023-06-22 |
Family
ID=67432317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575438A Pending JP2022537562A (ja) | 2019-06-18 | 2020-06-18 | Rna構築物 |
| JP2025081437A Pending JP2025118871A (ja) | 2019-06-18 | 2025-05-14 | Rna構築物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025081437A Pending JP2025118871A (ja) | 2019-06-18 | 2025-05-14 | Rna構築物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12569548B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3987042A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022537562A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220038669A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114402078B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020296337B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021024786A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3143117A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201908729D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL288956A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021015753A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020254804A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110168093B (zh) * | 2017-09-12 | 2023-08-15 | 中科蓝华(广州)生物医药技术有限公司 | 一种转染细胞内寄生虫的试剂盒及其应用 |
| WO2021194672A1 (en) | 2020-03-23 | 2021-09-30 | Hdt Bio Corp. | Compositions and methods for delivery of rna |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| EP4097475A4 (en) * | 2020-01-29 | 2024-05-22 | Helix Nanotechnologies, Inc. | METHODS AND COMPOSITIONS FOR NUCLEIC ACID EXPRESSION INVOLVING INHIBITION OF NF-KB PATHWAYS AND/OR IRF PATHWAYS |
| CN115768470A (zh) * | 2020-03-03 | 2023-03-07 | 火箭疫苗股份公司 | 用于疫苗生产以防范冠状病毒的全合成的长链核酸 |
| JP2023517644A (ja) | 2020-03-09 | 2023-04-26 | アークトゥラス・セラピューティクス・インコーポレイテッド | コロナウイルスワクチン組成物及び方法 |
| US12178921B2 (en) | 2020-08-14 | 2024-12-31 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| GB202020061D0 (en) * | 2020-12-17 | 2021-02-03 | Imp College Innovations Ltd | RNA construct |
| US20240301006A1 (en) | 2020-12-23 | 2024-09-12 | Glaxosmithkline Biologicals Sa | Self-amplifying messenger rna |
| WO2022234268A1 (en) | 2021-05-04 | 2022-11-10 | Mogrify Limited | Cell conversion |
| US20240254515A1 (en) * | 2021-05-26 | 2024-08-01 | The University Of British Columbia | Flexible expression vector systems and application of same to vaccines and immunotherapeutics |
| CN113249408B (zh) * | 2021-06-23 | 2021-11-02 | 深圳湾实验室 | 一种靶向激活体液免疫和细胞免疫的核酸疫苗载体构建及应用 |
| WO2023049636A2 (en) | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Cancer therapy compositions and uses thereof |
| JP2024535352A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | Sars-cov-2 rnaワクチン組成物および使用方法 |
| CA3232658A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Rna vaccines against infectious diseases |
| AU2022352486A1 (en) | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Dried nanoparticle compositions |
| CN118715325A (zh) * | 2021-12-17 | 2024-09-27 | 帝国理工创新有限公司 | Rna构建体 |
| GB202203060D0 (en) | 2022-03-04 | 2022-04-20 | Imperial College Innovations Ltd | RNA molecule |
| EP4522754A1 (en) * | 2022-05-12 | 2025-03-19 | Sunvax MRNA Therapeutics Inc. | Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator |
| CN115820696A (zh) * | 2022-07-28 | 2023-03-21 | 怡道生物科技(苏州)有限公司 | 治疗性多价HPV mRNA疫苗及其制备方法 |
| WO2024181753A1 (ko) * | 2023-02-27 | 2024-09-06 | 주식회사 마이크로유니 | 자가 증폭 rna 컨스트럭트 및 이의 용도 |
| CN122180770A (zh) | 2023-07-06 | 2026-06-09 | 帝国理工学院创新有限公司 | Rna分子 |
| CN121586776A (zh) * | 2023-07-19 | 2026-02-27 | 上海复诺健生物科技有限公司 | 自扩增核酸分子及其应用 |
| GB202313445D0 (en) | 2023-09-04 | 2023-10-18 | Imperial College Innovations Ltd | Rna molecule |
| WO2025217136A2 (en) * | 2024-04-08 | 2025-10-16 | Amplitude Therapeutics, Inc. | Trans-amplifying rnas encoding immunomodulators |
| GB202500051D0 (en) | 2025-01-03 | 2025-02-19 | Imperial College Innovations Ltd | RNA Molecule |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010537645A (ja) * | 2007-08-31 | 2010-12-09 | エーラス グローバル ティービー ワクチン ファウンデーション | I型インターフェロン応答抑制剤類の発現によるウイルスベースワクチンベクター類からのトランスジーン発現の増強 |
| US7608256B2 (en) | 2007-09-12 | 2009-10-27 | Aeras Global Tb Vaccine Foundation | Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response |
| US20140037680A1 (en) * | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| WO2014072061A1 (en) * | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
| EP4339287A3 (en) * | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| JP7788787B2 (ja) * | 2016-12-05 | 2025-12-19 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 遺伝子発現増強のための組成物および方法 |
-
2019
- 2019-06-18 GB GBGB1908729.5A patent/GB201908729D0/en not_active Ceased
-
2020
- 2020-06-18 WO PCT/GB2020/051465 patent/WO2020254804A1/en not_active Ceased
- 2020-06-18 JP JP2021575438A patent/JP2022537562A/ja active Pending
- 2020-06-18 US US17/617,831 patent/US12569548B2/en active Active
- 2020-06-18 MX MX2021015753A patent/MX2021015753A/es unknown
- 2020-06-18 CN CN202080045184.7A patent/CN114402078B/zh active Active
- 2020-06-18 BR BR112021024786A patent/BR112021024786A2/pt unknown
- 2020-06-18 EP EP20734803.8A patent/EP3987042A1/en active Pending
- 2020-06-18 AU AU2020296337A patent/AU2020296337B2/en active Active
- 2020-06-18 CA CA3143117A patent/CA3143117A1/en active Pending
- 2020-06-18 KR KR1020227001607A patent/KR20220038669A/ko active Pending
-
2021
- 2021-12-13 IL IL288956A patent/IL288956A/en unknown
-
2025
- 2025-05-14 JP JP2025081437A patent/JP2025118871A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210330781A1 (en) | Induce and enhance immune responses using recombinant replicon systems | |
| US8840899B2 (en) | Use of mTOR inhibitors to enhance T cell immune responses | |
| JP2023551982A (ja) | マルチシストロン性rnaワクチン及びその使用 | |
| US12533404B2 (en) | Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases | |
| CN112552379B (zh) | 合成肽在制备防治新型冠状病毒感染药物中的用途 | |
| US20190106682A1 (en) | Live, Attenuated Alphavirus Constructs and Methods and Uses Thereof | |
| JP2024535145A (ja) | 改変ワクシニアウイルスアンカラ(mva)による細胞傷害性導入遺伝子発現を下方調節するためのマイクロrnaの利用 | |
| JP2023519272A (ja) | エクソソームなどの脂質小胞を用いてコロナウイルスを標的にするための組成物および方法 | |
| Hidajat et al. | Next generation sequencing of DNA-launched Chikungunya vaccine virus | |
| JP2022512754A5 (cg-RX-API-DMAC7.html) | ||
| JP2024546964A5 (cg-RX-API-DMAC7.html) | ||
| Yonemitsu et al. | Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen | |
| JP2007516721A5 (cg-RX-API-DMAC7.html) | ||
| RU2022100963A (ru) | Рнк-конструкция | |
| WO2019029081A1 (zh) | 干扰素κ在制备抗囊膜病毒药物方面的应用 | |
| CN115975053B (zh) | 靶向新型冠状病毒的疫苗 | |
| US20160228531A1 (en) | Treatment of hepatitis d virus infections by redirection of t cells | |
| Dai et al. | Inhibition of ERK/MAPK suppresses avian leukosis virus subgroup A and B replication | |
| CN111748530B (zh) | 一种提高猪繁殖与呼吸综合征病毒体外培养感染量的方法及其应用 | |
| CN103865890B (zh) | 一种用于预防病毒性心肌炎的重组病毒及其疫苗和应用 | |
| CN110256536B (zh) | 一种抗丙型肝炎病毒感染合成肽及其应用 | |
| JPWO2018092887A1 (ja) | 非感染性パラミクソウイルス粒子を用いた感染症ワクチン | |
| WO2025149032A1 (en) | Respiratory syncytial virus vaccine compositions and their use | |
| Faulkner | Defining Determinants of Viral Membrane Protein Immunogenicity | |
| CN121653221A (zh) | 一种快速筛选抗寨卡病毒感染的激酶抑制剂的方法及应用 |